ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2

Abstract

The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.

1 - 53 . (canceled) 
     
     
         54 . A method for inhibiting angiogenesis comprising administering to a subject a soluble, non-aggregated anti-CD160 compound selected from the group consisting of anti-CD160 antibody, anti-CD160 antibody fragment, and anti-CD160 antibody derivative. 
     
     
         55 . The method of  claim 54 , wherein the anti-CD160 compound is administered in a pharmaceutical composition. 
     
     
         56 . The method of  claim 54 , wherein the anti-CD160 compound is anti-CD160 mAb CL1-R2. 
     
     
         57 . The method of  claim 54 , wherein administering the anti-CD 160 compound has an anti-angiogenic effect. 
     
     
         58 . The method of  claim 57 , wherein the anti-angiogenic effect is the inhibition of blood vessel formation and growth. 
     
     
         59 . The method of  claim 54 , wherein administering the anti-CD160 compound does not induce apoptosis of T cells. 
     
     
         60 . The method of  claim 54 , wherein the anti-CD160 compound is capable of competing with the anti-CD160 mAb CL1-R2 for binding to CD160. 
     
     
         61 . The method of  claim 54 , wherein the anti-CD160 compound does not bind to CD8αβ. 
     
     
         62 . The method of  claim 54 , wherein the anti-CD160 compound does not bind to CD85j. 
     
     
         63 . A method of treating a neo-vascularization-favored pathology selected from the group consisting of tumor growth, pre-eclampsia, eclampsia, diabetes, ischemic ocular disease, and rheumatoid arthritis by administering to a subject a soluble, non-aggregated anti-CD160 compound selected from the group consisting of anti-CD160 antibody, anti-CD160 antibody fragment, and anti-CD160 antibody derivative, said anti-CD160 compound having an anti-angiogenic effect of inhibiting blood vessel formation and growth, thereby relieving the subject of one or more symptoms associated with the pathology. 
     
     
         64 . The method of  claim 63 , wherein the pathology is tumor growth. 
     
     
         65 . The method of  claim 54 , wherein the conservative fragment of mAb CL1-R2 is a Fab, a Fab′, a F(ab)2, a F(ab′)2 or a Fv fragment of mAb CL1-R2.